Manufacturing delay can mar vax success: Research

Aditi Tandon

Tribune News Service

New Delhi, December 11

As nations gear for Covid-19 vaccination, a new research has shown that factors related to implementation will contribute more to the success of inoculation plans than vaccine’s efficacy.

The findings based on mathematical simulation of vaccination say the benefits of a Covid vaccine will decline substantially in the event of manufacturing or deployment delays, significant vaccine hesitancy, or greater epidemic severity.

Nod for mRNA vaccine trial

National drug regulator on Friday approved India’s first indigenous mRNA Covid vaccine candidate to start phase I & II human trials.

“There is an urgent need for health officials to invest greater financial resources and attention to vaccine production and distribution programmes, to redouble efforts to promote public confidence in Covid-19 vaccines, and to encourage continued adherence to other mitigation approaches, even after a vaccine becomes available,” says a new research published in Health Affairs, a leading health policy journal. Based on new findings, global vaccination experts, including India’s Gagandeep Kang, have urged countries to start engaging communities for building public confidence in Covid vaccines.

In the article “The Covid-19 vaccines rush: Participatory community engagement matters more than ever” published in The Lancet, Kang and others have said, “Policymakers must accelerate dialogue and support the development of community networks, leveraging and supporting existing local channels that influence decision making.”

Be the first to comment on "Manufacturing delay can mar vax success: Research"

Leave a comment

Your email address will not be published.


%d bloggers like this: